Evaluation of prevalence of  32 mutation in CCR5 gene in breast cancer patients in Rafsanjan city

• Main Authors: Mohammad Kazemi Arababadi, Mohammad Reza Mirzaei, Ebrahim Rezazadeh Zarandi, Gholamhossein Hassanshahi, Mohammad Reza Vatani Baf
• Format: Article
• Language: English
• Published: Mazandaran University of Medical Sciences 2009-01-01
• Series: Journal of Mazandaran University of Medical Sciences
• Subjects: Chemokine; CCR5;  32 and breast cancer
• Online Access: http://www.mazums.ac.ir/index.php?digital_library&do=downloadPdf&sid=754
• ISSN: 1735-9260; 1735-9279

(Received 24 August, 2008; Accepted 21 May, 2009)AbstractBackground and purpose: Chemokines and their receptors are expressed in different types of malignancies. CC chemokines MIP-1 (CCL3), MIP-1 (CCL4) and RANTES (CCL5) is believed to be anti-tumor and also aid to the metastasis in tumor microenvironment. CCR2 and CCR5 are special G-protein receptors for these chemokines. Due to the important role of CCR5 chemokine receptor in tumor biology, this project is designed to examine  32 mutation in CCR5 gene regards breast cancer.Materials and methods: This experimental study was performed during 2007-8 on 100 healthy adults and 36 breast cancer patients by Gap-PCR. The demographic information also was collected by questionner and t-test Chi-square was used for statistical analysis of data.Results: Our results showed that none of breast cancer patients had CCR5- 32 mutation while 3 (3%) cases of controls had heterozygotic form of this mutation.Conclusion: Our results showed that there is not any CCR5- 32 mutation in patients. Therefore, it appears that this mutation don’t play any role in breast cancer.J Mazand Univ Med Sci 2009; 19(70): 49-53 (Persian)